20/20 Biolabs, Inc. Common Stock (AIDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
20/20 Biolabs, Inc. Common Stock stock (AIDX) is currently trading at $1.64. 20/20 Biolabs, Inc. Common Stock PS ratio (Price-to-Sales) is 10.08. WallStSmart rates AIDX as Sell.
- AIDX PE ratio analysis and historical PE chart
- AIDX PS ratio (Price-to-Sales) history and trend
- AIDX intrinsic value — DCF, Graham Number, EPV models
- AIDX stock price prediction 2025 2026 2027 2028 2029 2030
- AIDX fair value vs current price
- AIDX insider transactions and insider buying
- Is AIDX undervalued or overvalued?
- 20/20 Biolabs, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- AIDX Piotroski F-Score and Altman Z-Score
- AIDX analyst price target and Smart Rating
20/20 Biolabs, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
20/20 Biolabs, Inc. Common Stock (AIDX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
20/20 Biolabs, Inc. Common Stock (AIDX) Key Strengths (0)
20/20 Biolabs, Inc. Common Stock (AIDX) Areas to Watch (7)
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 10.1x annual revenue
Very expensive at 341.4x book value
Very low institutional interest at 0.00%
Micro-cap company with very limited liquidity and high volatility
Solid revenue growth at 15.80% per year
Supporting Valuation Data
20/20 Biolabs, Inc. Common Stock (AIDX) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (10.08), Price/Book (341.42) suggest expensive pricing. Growth concerns include Revenue Growth at 15.80%, which may limit upside. Profitability pressure is visible in Operating Margin at -191.40%, Profit Margin at -159.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -191.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 15.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AIDX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AIDX's Price-to-Sales ratio of 10.08x trades 25% below its historical average of 13.51x (14th percentile). The current valuation is 48% below its historical high of 19.34x set in Mar 2026, and 6% above its historical low of 9.52x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~19.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for 20/20 Biolabs, Inc. Common Stock (AIDX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
20/20 Biolabs, Inc. Common Stock is a strong growth company balancing expansion with improving profitability. Revenue reached 2M with 16% growth year-over-year. The company is currently unprofitable, posting a -159.3% profit margin.
Key Findings
The company is unprofitable with a -159.3% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -536,451, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact 20/20 Biolabs, Inc. Common Stock.
Bottom Line
20/20 Biolabs, Inc. Common Stock offers an attractive blend of growth (16% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About 20/20 Biolabs, Inc. Common Stock(AIDX)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
20/20 Biolabs, Inc. (ticker: AIDX) is a biotechnology company focused on providing innovative solutions for genomic research and diagnostics. The company specializes in delivering advanced laboratory services that enhance the accuracy and efficiency of genetic testing, catering to both clinical and research markets. With a commitment to leveraging cutting-edge technologies, 20/20 Biolabs aims to redefine the standards of molecular diagnostics and contribute significantly to the advancement of personalized medicine. As the demand for genomic data continues to rise, the company's strategic initiatives position it well for growth in this rapidly evolving sector.